If CMS is to write a template for other states, or if Congress is to buy this design at national scale, it is important to ...
Jack Hoadley of Georgetown University breaks down how the No Surprises Act’s dispute resolution process has grown into a ...
Access to medication is not the same as delivery of a cure. Without defined delivery obligations, federal funds risk financing treatment courses rather than completed cures.
PhD, MS, BPharm, is a health economist and was a doctoral student at the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute in the School of Pharmacy at the University of Washington ...
The final “public charge” rule broadens the range of benefits used in determining public charge status, allows officials to ...
Despite the FTC’s promises, its settlements with PBMs will not be fully effective at accomplishing their stated goals. One ...
CMS and state Medicaid agencies should consider several factors related to the ACO LEAD (ACO Long-Term Enhanced Design) model ...
Allison M. Nishi is a research assistant at the Harvard T.H. Chan School of Public Health in Boston, Massachusetts. CMS and state Medicaid agencies should consider several factors related to the ACO ...
Many historians and public health research scholars talk about their desire to influence policy, but no one did it better ...
The United States has experienced unprecedented, sustained population aging in the last century and a quarter. In 1900, ...
Dan Arnold discusses the growth of Medicaid-funded autism treatment, the influence of private equity, and the challenge of ...
The existence of duplicative discounts in the Bridge Program likely represents an unintended consequence of its design that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results